BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 3648093)

  • 1. Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B.
    Perez HD; Hooper C; Volanakis J; Ueda A
    J Immunol; 1987 Jul; 139(2):484-9. PubMed ID: 3648093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphonuclear leukocyte chemotaxis in systemic lupus erythematosus.
    Perez HD; Goldstein IM
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():53-8. PubMed ID: 3612652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
    Perez HD; Lipton M; Goldstein IM
    J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the chemotactic activity of human C5a des Arg by an anionic polypeptide ("cochemotaxin") in normal serum and plasma.
    Perez HD; Goldstein IM; Webster RO; Henson PM
    J Immunol; 1981 Feb; 126(2):800-4. PubMed ID: 7451994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity.
    Perez HD; Chenoweth DE; Goldstein IM
    J Clin Invest; 1986 Dec; 78(6):1589-95. PubMed ID: 3782473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts.
    Senior RM; Griffin GL; Perez HD; Webster RO
    J Immunol; 1988 Nov; 141(10):3570-4. PubMed ID: 3183381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
    Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
    J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity.
    Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI
    J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.
    Charo IF; Yuen C; Perez HD; Goldstein IM
    J Immunol; 1986 May; 136(9):3412-9. PubMed ID: 3514759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.
    Marder SR; Chenoweth DE; Goldstein IM; Perez HD
    J Immunol; 1985 May; 134(5):3325-31. PubMed ID: 3884709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (group-specific component globulin).
    Perez HD; Kelly E; Chenoweth D; Elfman F
    J Clin Invest; 1988 Jul; 82(1):360-3. PubMed ID: 3392212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotactic factor inactivator interaction with Gc-globulin (vitamin D-binding protein). A mechanism of modulating the chemotactic activity of C5a.
    Robbins RA; Hamel FG
    J Immunol; 1990 Mar; 144(6):2371-6. PubMed ID: 2313096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic identification of chemotactic factor inactivator in normal human serum and bronchoalveolar lavage fluid.
    Robbins RA; Rasmussen JK; Clayton ME; Gossman GL; Kendall TJ; Rennard SI
    J Lab Clin Med; 1987 Sep; 110(3):292-9. PubMed ID: 3611952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monocyte adherence: a primary effect of chemotactic factors on the monocyte to stimulate adherence to human endothelium.
    Doherty DE; Haslett C; Tonnesen MG; Henson PM
    J Immunol; 1987 Mar; 138(6):1762-71. PubMed ID: 3819394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg.
    Kew RR; Webster RO
    J Clin Invest; 1988 Jul; 82(1):364-9. PubMed ID: 3392213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement (C5)-derived chemotactic activity in serum from patients with pancreatitis.
    Perez HD; Horn JK; Ong R; Goldstein IM
    J Lab Clin Med; 1983 Jan; 101(1):123-9. PubMed ID: 6848611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of C5a antagonist by synovial and peritoneal tissue fibroblasts.
    Matzner Y; Gavison R; Shlomai Z; Ben-Bassat H; Liebergal M; Robinson DR; Babior BM
    J Cell Physiol; 1986 Nov; 129(2):215-20. PubMed ID: 3771654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
    Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
    Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of induction of IL-1 production in human monocytes by complement fragments.
    Arend WP; Massoni RJ; Niemann MA; Giclas PC
    J Immunol; 1989 Jan; 142(1):173-8. PubMed ID: 2783323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin.
    Takematsu H; Tagami H
    Arch Dermatol; 1993 Jan; 129(1):74-80. PubMed ID: 8420495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.